Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25554640 | 0.90 | SCN9A (0.33) | KDM1AGPR119ALOX5APFEN1CYP19A1 | |
| SCHEMBL30353119 | 0.89 | KDM1A (0.37) | KDM1AMAOAALOX5APFEN1CYP19A1 | |
| SCHEMBL25554348 | 0.89 | KDM1A (0.37) | KDM1AMAOAALOX5APFEN1CYP19A1 | |
| SCHEMBL30257448 | 0.88 | KDM1A (0.36) | KDM1AMAOAALOX5APFEN1CYP19A1 | |
| SCHEMBL25554123 | 0.88 | KDM1A (0.36) | KDM1AMAOAALOX5APFEN1CYP19A1 | |
| SCHEMBL25554475 | 0.87 | KDM1A (0.36) | KDM1AMAOAGPR119ALOX5APFEN1 | |
| SCHEMBL25058502 | 0.86 | KDM1A (0.40) | KDM1AMAOAALOX5APFEN1CYP19A1 | |
| SCHEMBL30257482 | 0.84 | FEN1 (0.36) | KDM1AMAOAALOX5APFEN1CYP19A1 | |
| SCHEMBL25554184 | 0.84 | FEN1 (0.36) | KDM1AMAOAALOX5APFEN1CYP19A1 | |
| SCHEMBL25554560 | 0.84 | NSD2 (0.34) | KDM1AALOX5APFEN1CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| EP-4137481-A1 | ARYL OR HETEROARYL DERIVATIVE | Teijin Pharma Limited (JP) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | ARRB1, NR3C2, TRPC6 | KDM1A 4415/4885MAOA 4383/4885GPR119 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.